Craif raised a ¥5.28 billion Series D to fund U.S. clinical research, pancreatic cancer studies, regulatory filings, and commercialization.
- Amount
- $33.1M
- Stage
- Series D
- Announced
- 18 August 2026
- Leads
- Granite-Integral, TAUNS Laboratories, Inc.
- Other investors
- Unreasonable, X&KSK
- Use of funds
- U.S. clinical R&D in San Diego, pancreatic cancer clinical study, U.S. commercial launch preparation, and Japanese SaMD regulatory filing.
- Total raised
- $88M to date
- Checked
- Amount and date matched across 2 press sources